What Researchers Did
Researchers conducted a prospective case series to evaluate the effect of hyperbaric oxygen therapy on patients with refractory ulcerative colitis, using clinical and histopathological scoring.
What They Found
All patients showed clinical improvement by the 40th cycle of hyperbaric oxygen therapy, with a significant drop in median stool frequency from 7 to 1 motion per day (p<0.001). Additionally, none of the patients had persistent blood passage after treatment (p=0.002), and histological analysis revealed reduced disease activity and increased colonic stem cell proliferation (p=0.001).
What This Means for Canadian Patients
Hyperbaric oxygen therapy may offer a new treatment option for Canadian patients with refractory ulcerative colitis who have not responded to conventional therapies. This therapy appears to promote mucosal healing by stimulating colonic stem cells, potentially leading to improved symptoms and quality of life.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada or with Canadian participants.
Study Limitations
A key limitation of this study is its design as a prospective case series, which typically involves a small number of participants and lacks a control group, limiting the generalizability of the findings.